After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.
NEW YORK – AstraZeneca on Monday said it has inked an exclusive license agreement with Shijiazhuang, China-based CSPC Pharmaceutical Group to develop an early-stage small molecule lipoprotein(a) ...
Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.
Four US cancer centers are partnering with leading technology firms to analyze cancer patient data while maintaining privacy and regulatory compliance.